2e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human CD30, His Tag (Cat. No.CD0-HF2H4) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).
5e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD30, His Tag (Cat. No. CD0-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Loaded Human CD30 Ligand, His Tag, low endotoxin (Cat. No. CDL-H524b) on HIS1K Biosensor, can bind Human CD30, Llama IgG2b Fc Tag, low endotoxin (Cat. No. TN8-H5250) with an affinity constant of 55.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Brentuximab vedotin | cAC10-vcMMAE; cAC10-Val-Cit-MMAE; SGN-30; SGN-35; cAC-10; SGD-1010 | Approved | Millennium Pharmaceuticals Inc, Seattle Genetics Inc | 安适利, Adcetris | Mainland China | Mycosis Fungoides; Lymphoma, Primary Cutaneous Anaplastic Large Cell | Bsp Pharmaceuticals Spa | 2011-08-19 | Lupus Erythematosus, Systemic; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Lymphomatoid Papulosis; Mycosis Fungoides; Scleroderma, Diffuse; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Sezary Syndrome; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Mast-Cell; Enteropathy-Associated T-Cell Lymphoma; Scleroderma, Systemic; Myelodysplastic Syndromes; Mastocytosis, Systemic; Graft vs Host Disease; Hodgkin Disease; Anemia, Refractory, with Excess of Blasts; HIV Infections; Hematologic Diseases; Solid tumours; Lymphoma, T-Cell, Peripheral | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-CD30 CAR-T cell therapy (National Cancer Institute) | Hu30-CD28z | Phase 1 Clinical | National Cancer Institute | Lymphoma | Details |
| CD30.CAR | H-27721; CD30.CAR | Phase 1 Clinical | Baylor College Of Medicine | Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
| Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) | CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta | Phase 2 Clinical | Pla General Hospital | Hodgkin Disease | Details |
| EBV-specific-CAR.CD30 | EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System | Hodgkin Disease; Lymphoma, Non-Hodgkin | Details |
| ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) | Phase 2 Clinical | Unc Lineberger Comprehensive Cancer Center | Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin | Details | |
| HSP-CAR-30 | HSP-CAR-30 | Phase 2 Clinical | Fundació Institut De Recerca De L | Hodgkin Disease; Lymphoma, T-Cell | Details |
| SGN-CD30C | SGN-CD30C | Phase 1 Clinical | Seattle Genetics | Lymphoma | Details |
| CD30.CAR-EBVST cell therapy (Baylor College of Medicine) | TT-11X | Phase 1 Clinical | Baylor College Of Medicine, Tessa Therapeutics | Lymphoma, Large B-Cell, Diffuse | Details |
| Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30，Shanghai Unicar-Therapy Bio-medicine) | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Details | |||
| Anti CD30 CAR T Cell Therapy (First Song Therapeutics) | Zhejiang University | Details | |||
| MDX-1401 | MDX-1401 | Medarex | Details | ||
| Itezocabtagene autoleucel | TT-11 | Tessa Therapeutics | Details | ||
| Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) | Phase 1 Clinical | Wuhan Bio-Raid Biotechnology | Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic | Details | |
| XmAb-2513 | XmAb-2513 | Xencor | Details | ||
| Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) | Immune Cell | Details | |||
| AFM-13 | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Mycosis Fungoides | Details |
| Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 | F0002-ADC; B-006 | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
